Hepatitis Monthly

Published by: Kowsar

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran

Alireza Mehrazmay 1 , Seyed Moayed Alavian 1 , * , Maziar Moradi-Lakeh 2 , Mahdi Mokhtari Payam 2 , Amir Hashemi-Meshkini 3 , 4 , Bita Behnava 1 , Seyyed Mohammad Miri 1 , Pegah Karimi Elizee 1 , Seyed Vahid Tabatabaee 1 , Maryam Keshvari 1 and Kamran Bagheri Lankarani 5
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah Hospital, Tehran, IR Iran
2 Department of Community Medicine, School of Medicine, Gastrointestinal and Liver Disease Research Center (GILDRC), Iran University of Medical Science, Tehran, IR Iran
3 Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
4 Non-Communicable Disease Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
5 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: September 2013, 13 (9); e10236
  • Published Online: September 1, 2013
  • Article Type: Research Article
  • Received: January 12, 2013
  • Revised: June 23, 2013
  • Accepted: July 15, 2013
  • DOI: 10.5812/hepatmon.10236

To Cite: Mehrazmay A, Alavian S M, Moradi-Lakeh M, Mokhtari Payam M, Hashemi-Meshkini A, et al. Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran, Hepat Mon. 2013 ;13(9):e10236. doi: 10.5812/hepatmon.10236.

Abstract
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2): 47-52[PubMed]
  • 2. World Health Organization . Hepatitis C. Fact sheet N°164. 2013;
  • 3. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55 Suppl 1-5[DOI][PubMed]
  • 4. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an Emerging Infection. Arch Iran Med. 2005; 8(2): 84-90
  • 5. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008; 93(8): 1247-51[DOI][PubMed]
  • 6. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2197-223[DOI]
  • 7. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998; 27(1): 209-12[DOI][PubMed]
  • 8. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000; 68(5): 556-67[DOI][PubMed]
  • 9. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001; 33(2): 433-8[DOI][PubMed]
  • 10. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010; 10(2): 121-31[PubMed]
  • 11. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138(1): 116-22[DOI][PubMed]
  • 12. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51(4): 1176-84[DOI][PubMed]
  • 13. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007; 14(10): 721-9[DOI][PubMed]
  • 14. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138(1): 108-15[DOI][PubMed]
  • 15. Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006; 45(2): 204-13[DOI][PubMed]
  • 16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998; 352(9138): 1426-32[DOI]
  • 17. Alavian SM, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, Abar K. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004; 4(7): 53-8
  • 18. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012; 12(6): 372-81[DOI][PubMed]
  • 19. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm. 2005; 11(8): 687-94[PubMed]
  • 20. Edejer TTT. Making Choices In Health: Who Guide To Cost Effectiveness Analysis. 2003;
  • 21. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004; 99(8): 1490-6[DOI][PubMed]
  • 22. Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg. 2007; 70(2): 177-87[PubMed]
  • 23. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006; 55(9): 1332-8[DOI][PubMed]
  • 24. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003; 290(2): 228-37[DOI][PubMed]
  • 25. Liu J, Lin CS, Hu SH, Liang ML, Zhao ZX, Gao ZL. [Quality of life in patients with chronic hepatitis C after PEG-Interferon a-2a therapy]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(12): 890-3[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader